Harsh Parmar, MD

Harsh Parmar, MD, is an associate professor of medicine at Hackensack University Medical Center.

Articles by Harsh Parmar, MD

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

May 17th 2025

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

Harsh Parmar, MD

Articles by Harsh Parmar, MD

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Latest Updated Articles

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

An Interview With Lucio Gordan, MD: Community Oncology and CAR T-Cell Therapy

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Harsh Parmar, MD

Articles by Harsh Parmar, MD

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Latest Updated Articles

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

An Interview With Lucio Gordan, MD: Community Oncology and CAR T-Cell Therapy

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma